Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that the initial clinical data from the safety study for Symphony? was presented by Renzo Cecere, M.D., FRCSC, FACS, Associate Professor of Surgery at McGill University, during the late-breaking clinical trials session at the Society of Thoracic Surgeons (STS) 2012 Annual Meeting in Fort Lauderdale, Florida.

The presentation, "Initial Safety Trial of an Implantable, Synchronous, Partial Circulatory Support Device: Symphony?," discussed the initial clinical data from the Symphony safety trial being conducted outside of the U.S., and was presented during one of the four late-breaking clinical trials sessions at the STS 2012 Annual Meeting.

The presentation included analysis of the initial first-in-man experience, originally announced in December 2011, which demonstrated feasibility of the synchronized, implantable heart pump called Symphony. The analysis indicated a marked improvement in cardiac output, improved renal function, short intensive care unit (ICU) stay and early patient mobility post implant.

"The concept of a minimally invasive implantable pump for patients in chronic heart failure, coupled with the ability to remodel the heart, is unique and groundbreaking and we are very pleased with the initial findings of Symphony," said Dr. Cecere.

Symphony is designed to treat approximately 90,000 of the 1.6 million New York Heart Association (NYHA) Class III chronic heart failure patients by improving patient hemodynamics and potentially improving quality of life. The device is designed with the primary goal of lowering hospital costs by stabilizing the progression of heart failure and/or recovering/remodeling the heart.

Symphony is not currently approved for use in the United States.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recent Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Abiomed
Aimee Maillett, 978-646-1553
Public Relations Specialist
amaillett@abiomed.com